Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI, a neurokinin-1 receptor antagonist aprepitant for the prevention of CINV; and HTX-011, which is in Phase III clinical development for the prevention of post-operative pain. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-251-4400
Debt
Current Ratio7.18
Quick Ratio6.69
Price-To-Earnings
Sales & Book Value
Annual Sales$30.77 million
Price / Sales68.35
Price / Cash Flow8.64
Price / Book13.28
Profitability
Net Income$-197,480,000.00
Net Margins-326.79%
Return on Assets-54.83%
Miscellaneous
Employees145
OptionableOptionable
Heron Therapeutics (NASDAQ:HRTX) Frequently Asked Questions
What is Heron Therapeutics' stock symbol?
Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."
How were Heron Therapeutics' earnings last quarter?
Heron Therapeutics Inc (NASDAQ:HRTX) issued its quarterly earnings data on Wednesday, November, 7th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.05. The biotechnology company earned $19.79 million during the quarter, compared to the consensus estimate of $19.84 million. Heron Therapeutics had a negative return on equity of 72.23% and a negative net margin of 326.79%. The company's revenue for the quarter was up 130.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.77) earnings per share. View Heron Therapeutics' Earnings History.
When is Heron Therapeutics' next earnings date?
What guidance has Heron Therapeutics issued on next quarter's earnings?
Heron Therapeutics updated its FY 2018 earnings guidance on Monday, January, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $76.7-76.7 million, compared to the consensus revenue estimate of $72.41 million.Heron Therapeutics also updated its Q4 2018 guidance to EPS.
What price target have analysts set for HRTX?
11 brokerages have issued 12 month price objectives for Heron Therapeutics' shares. Their forecasts range from $41.00 to $80.00. On average, they anticipate Heron Therapeutics' stock price to reach $53.70 in the next year. This suggests a possible upside of 97.0% from the stock's current price. View Analyst Price Targets for Heron Therapeutics.
What is the consensus analysts' recommendation for Heron Therapeutics?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Heron Therapeutics.
What are Wall Street analysts saying about Heron Therapeutics stock?
Here are some recent quotes from research analysts about Heron Therapeutics stock:
- 1. According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (1/9/2019)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and expect upward earnings revisions, along with an approval of HTX-011, to drive HRTX shares higher. We expect upside to come from Cinvanti and HTX-011. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to reach our 12-month price target of $50." (12/31/2018)
- 3. Mizuho analysts commented, "We expect HTX-011 to receive broad label and we see potential for a quicker review process by the FDA for a mid-2019 approval. We reiterate our Buy rating and raise our PT to $41." (6/22/2018)
- 4. Cowen Inc analysts commented, "We are still waiting to speak with the company and have thus not yet updated our model and price target, but do not recommend buying on weakness." (3/19/2018)
Has Heron Therapeutics been receiving favorable news coverage?
Media coverage about HRTX stock has trended somewhat negative on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Heron Therapeutics earned a news sentiment score of -1.6 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term.
Who are some of Heron Therapeutics' key competitors?
Some companies that are related to Heron Therapeutics include Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Loxo Oncology (LOXO), SAGE Therapeutics (SAGE), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), GALAPAGOS NV/S (GLPG), Alkermes (ALKS), United Therapeutics (UTHR) and Catalent (CTLT).
Who are Heron Therapeutics' key executives?
Heron Therapeutics' management team includes the folowing people:
- Dr. Barry D. Quart, CEO & Director (Age 61)
- Mr. Robert H. Rosen, Pres & Director (Age 62)
- Mr. Robert E. Hoffman CPA, CFO & Sr. VP of Fin. (Age 52)
- Ms. Kimberly J. Manhard, Exec. VP of Drug Devel. (Age 58)
- Mr. David L. Szekeres, Sr. VP of Bus. Devel., Gen. Counsel & Corp. Sec. (Age 44)
Who are Heron Therapeutics' major shareholders?
Heron Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Private Asset Management Inc. (0.12%) and Boston Advisors LLC (0.03%). Company insiders that own Heron Therapeutics stock include Barry D Quart, Kevin C Tang, Kimberly Manhard, Robert Hoffman and Robert Rosen. View Institutional Ownership Trends for Heron Therapeutics.
Which institutional investors are buying Heron Therapeutics stock?
How do I buy shares of Heron Therapeutics?
Shares of HRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Heron Therapeutics' stock price today?
One share of HRTX stock can currently be purchased for approximately $27.26.
How big of a company is Heron Therapeutics?
Heron Therapeutics has a market capitalization of $2.08 billion and generates $30.77 million in revenue each year. The biotechnology company earns $-197,480,000.00 in net income (profit) each year or $3.65 on an earnings per share basis. Heron Therapeutics employs 145 workers across the globe.
What is Heron Therapeutics' official website?
How can I contact Heron Therapeutics?
Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-251-4400 or via email at [email protected]
MarketBeat Community Rating for Heron Therapeutics (NASDAQ HRTX)
MarketBeat's community ratings are surveys of what our community members think about Heron Therapeutics and other stocks. Vote "Outperform" if you believe HRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
